ENDEAVOR VENTURE FUNDS & VENTURE STUDIO
Gershon Capital has two companies, Endeavor Venture Fund established in 2009, and its Venture Studio Arm established in 2022
Dr. Martin Alexander Gershon is the Managing Partner and CIO of Endeavor Venture Funds and Endeavor Venture Studio
We recognize that we are at the cusp of the 4th Industrial Revolution, where advances in technology, medicine & science will significantly accelerate the development of new novel drugs, devices, services & our own overall personal well being & health status. With this sea change we believe there are tremendous opportunities to lead with new business models. More than ever, we need to develop the next generation of leaders to commercialize scientific discoveries. In 2022 Endeavor launched the Life Sciences Venture Studio to leverage our ecosystem to accelerate the growth of the next wave of Unicorns.
As the Managing Partner Dr. Gershon is the architect driving a team of 22 professionals to leverage Endeavor’s ecosystem of collaboration partnerships to provide CEO/Entrepreneurs Founders with bespoke revenue generating Go-to-Market strategies, FDA regulatory services, clinical trial design and reimbursement and coding guidance, and the development of strategic and financial corporate partnerships to grow, scale, and commercialize disruptive new healthcare and life sciences products and services stemming from technologies like AI and ML.
Over the past 23 years Endeavor has expanded and developed an ecosystem of collaboration partners with Big Tech Companies, Digital Healthcare, Pharma, Biotech, Medtech and Healthtech, leveraging the core competencies of the partnerships and providing transformative innovation and technology solutions to emerging healthcare companies. With this ecosystem Endeavor designs strategies for CEO/Founders to improve their business performance, use big data more intelligently, and accelerate revenue generating implications of new technologies such as AI and Machine Learning. Endeavor particularly targets emerging Digital Unicorns in Healthcare and Life Sciences to design strategies to expand AI Healthcare use cases in collaboration with Big Tech and Cloud Providers, providing companies with bespoke growth strategies that accelerate commercialization and generate new stand alone revenue streams. This hyper growth often leads to the development of financial partnerships and syndicated venture investment opportunities within our network of 200 venture partners and corporate venture accelerators and our venture arm, Endeavor Venture Funds.
Endeavor Venture Fund is an evergreen Swiss healthcare and life sciences venture fund established in 2009, with 140 investments in 94 companies providing funding of up to $75M. The Fund provides capital and strategic guidance for great entrepreneurs and innovative emerging life science companies that possess disruptive technologies with strong commercial potential leveraging ground breaking innovation and technology in healthcare AI, digital health, personalized health, precision medicine, wearable sensors, 3-D imaging, drug discovery, 3-D printing, telemedicine, VR and Digital Twin technologies, quantum computing, medical devices, molecular biomarkers, biotechnology, gene therapy, and health and wellness.
Endeavor Venture Studio: The Alternative to Accelerators
Endeavor Venture Studio provides up to $5M of funding, strong strategic partnerships and hands on guidance and operational support with seasoned entrepreneurs, subject matter experts and business leaders to help grow, scale and commercialize the company’s products or services.
Endeavor Venture Studio acts as a founding partner with startups incubating their own ideas or ideas from our partners. The studio’s internal team builds the minimum viable product, then validates the idea by finding product/market fit and leveraging all of the resources of Endeavor Life Sciences Growth Advisors, to design bespoke go-to-market strategies that accelerate growth and build platforms and multiple vertical revenue streams. Examples of companies that have emerged from venture studios include Moderna.
90% of startups fail in the first 3 years. Not because they run out of money as most CEOs believe, but because they don’t know how to put the right team, partnerships, and strategies together and don’t have the team to implement revenue accelerating go-to-market strategies (which are often flawed).
They lack key partnership and collaborators, and are often fearful of sharing their ideas because they believe their product is so unique and so valuable that everyone wants to steal it. This is just poor judgment and leads to a death spiral of isolation, going it on your own, and ultimately then running out of money and failing. It’s the lack of leadership and vision that leads to running out of money. Not as most CEOs believe, running out of money as the great driver of failure.
Endeavor Venture Studio addresses these problems with proven solutions for success. Once you know how to be successful, you can template it. And that’s what separates Endeavor Venture Fund. We have over 25 years of experience in building and exiting great healthcare and life science businesses, all supported by our ecosystem of Big Tech, Big Pharma, MedTech, Biotech, HealthTech, and Prominent Academic Institutions like Harvard, MIT, Boston University, McGill University, NYU, and Columbia University. We partner with the largest Fortune 500 Companies and greatest institutions to help provide a problem solved ecosystem at the hands of great CEO/Entrepreneurs who are committed to growing, commercializing and scaling the next great healthcare and life science Unicorns.
A study of 23 leading venture studios found that of the 415 companies they created, only 9% have failed.
Endeavor has created an ecosystem that creates resilient CEO/Entrepreneurs and sustainable funding for development, growth, commercialization and scalability from Seed Stage to Series B. Endeavor has designed a funnel within our ecosystem that ultimately moves our companies into Corporate Accelerators and Corporate Venture who collectively have dedicated several billion dollars to advance the companies with a clear entry and exit path of increasing investment and integration into their corporate ecosystem leading to eventual acquisition. The Future4Care accelerator, for example, includes Sanofi, Capgemini, Orange, and Generali, and stands out as an important part of our thematic investing. The accelerator has made 80 investments in digital healthcare companies since 2021, most recently investing $1.2B in early stage companies that fulfill Sanofi’s mission to become a digital healthcare company.
Our Strategy is to leverage our deep subject matter expertise, strategic vision, strong ecosystem in venture, family funds, high net worth individuals & angel investor communities, deep relationships with Big Tech, Pharma, MedTech, HealthTech, Biotech & Prominent Universities to ADVISE and INVEST in amazing early stage healthcare & life science companies to accelerate growth, and scale & commercialize groundbreaking new products on the road to becoming the next great Unicorn.
With more than 625% growth in the venture studio market over the last seven years venture studios have a shot at remaking the entrepreneurial ecosystem as we know it.
Medical, Legal, Regulatory & Operational Expertise
We leverage 20 years of experience in science, medicine, FDA/regulatory affairs, and industry to analyze companies at a highly technical level. This detailed analysis defines our due diligence process and gives syndicate investors a high level of confidence in our portfolio companies.
Strong Relationships & Professional Networks
Our long standing relationships and professional affiliations with the most respected institutional investment funds, academic centers and industry leaders allows us to provide high level strategic guidance, technical advisory services, operational support, and cross boarder deal syndication.
Global Reach & Efficient Access to Capital
We believe that global access to capital and financing is critical for our clients and counterparties who are looking for efficient transactions. Our global footprint and integrated networks allows us to access over 200 institutional, strategic, and high net worth investors in the US, Europe, and the Middle East.
Social Impact
Endeavor Life Sciences is committed to social entrepreneurship and advancement of health and wellness in countries throughout the world and is proud to invest in companies that advance socially important goals in healthcare.
.
.